Immunovia’s vision is to lead the way in bioinformatic-assisted diagnostics towards a future where all patients are diagnosed in time for effective treatment, better quality of life and significantly improved survival.
Our focus is to develop best in class diagnostics tests for early detection using state of the art technologies, including Immunovia’s proprietary protein microarray platform IMMray™.
Immunovia’s proprietary platform, IMMray™, uses a small volume of blood to measure proteins in a highly multiplexed fashion. IMMray™ microarrays are based on recombinant antibodies from Immunovia´s proprietary antibody library.
Immunovia headquarters in Lund houses a state of the art facility for producing antibodies and printing microarrays for proteomics analysis using robotic systems and high-throughput processes.
Immunovia’s quality systems will meet the regulatory requirements for ISO 13485 and 15189.
Immunovia plans to deploy patient testing from accredited laboratories. Read more about our Immunovia Dx Laboratory, Lund and Immunovia Inc, Marlborough.
If you are interested in partnering with us on our clinical trials or other joint offerings for your patients, please reach out at partners@immunovia.com.
We are interested in innovative research opportunities and collaborations that could impact early detection and early stage cancer. If you would like to work with us, please reach out at partners@immunovia.com.
